VCAM1 and atherosclerosis: These results indicate that our novel anti-VCAM-1 mAbs can effectively inhibit monocyte adhesion and transmigration in vitro, supporting the therapeutic rationale of VCAM-1 immunoblockade for the targeted treatment of atherosclerosis.